Microdosing psilocybin for chronic pain: a case series
In a three‑patient case series, self‑administered sub‑psychedelic (micro) doses of psilocybin produced robust analgesia and reduced reliance on conventional analgesics for chronic neuropathic pain, with minimal cognitive or somatic adverse effects. Effects were enhanced and sometimes prolonged by functional exercise, and repeated dosing suggested possible plasticity‑mediated cumulative benefit, warranting controlled investigation.
Authors
- Lyes, M.
- Yang, K. H.
- Castellanos, J. P.
Published
Abstract
Psychedelic serotonergic agonists such as psilocybin have recently been shown to produce sustained benefit in refractory depression, end of life anxiety, and addiction when administered in hallucinogenic doses and coupled with psychotherapy. Although it has been suggested that similar high-dose protocols may help chronic pain conditions, there are few published clinical trials of psychedelics for pain. The use of these agents in subpsychedelic doses for chronic pain management has received even less attention. This case series details the experiences of 3 individuals who have used low-dose psilocybin to manage chronic neuropathic pain. Although the nature and etiology of each patient's pain vary, they share a common experience, including inefficacy of current therapeutics and decreased quality of life. Through self-administration of psilocybin, these patients have achieved robust pain relief with decreased reliance on traditional analgesic medications. Despite varying preparations and uncertain potencies, the analgesic effects for all 3 patients occurred at doses without a psychedelic experience and with minimal cognitive or somatic adverse effects. Furthermore, the efficacy of pain relief and, in some cases, the duration of the effect were magnified when coupled with functional exercise. In addition, in 1 case, repeated dosing seemed to produce increased relief, suggesting a possible long-term plasticity-mediated effect. These commonalities highlight psilocybin's therapeutic potential in the treatment of chronic pain that warrants further investigation.
Research Summary of 'Microdosing psilocybin for chronic pain: a case series'
Introduction
Interest in medical applications of classic serotonergic psychedelics, particularly 5-HT2A agonists such as psilocybin, has risen due to recent trials showing benefit in treatment-resistant psychiatric disorders. Earlier clinical work and preliminary contemporary reports also suggest these agents can have analgesic effects, including in migraine/cluster headache and phantom limb pain. However, full-psychedelic (hallucinogenic) dosing is often accompanied by profound perceptual and cognitive effects that limit routine clinical utility, and there are few controlled trials of psychedelics for chronic pain. Microdosing—administration of sub-psychedelic amounts—has been less studied; one prior randomized trial found low-dose LSD attenuated acute pain in healthy volunteers, but systematic characterisations of microdosing for chronic pain are lacking. This case series, presented by Lyes and colleagues, aims to document the experiences of three patients who self-administered low (sub-hallucinogenic) doses of psilocybin-containing mushrooms to manage chronic neuropathic pain. The investigators sought to describe dosing patterns, onset and duration of analgesia, perceived benefits and off-target effects, and the role of psilocybin as an adjunct to physical therapy or in reducing opioid use, in order to inform future controlled research.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topics
- APA Citation
Lyes, M., Yang, K. H., Castellanos, J., & Furnish, T. (2023). Microdosing psilocybin for chronic pain: a case series. Pain, 164(4), 698-702. https://doi.org/10.1097/j.pain.0000000000002778
References (16)
Papers cited by this study that are also in Blossom
Andersson, M., Persson, M., Kjellgren, A. · Harm Reduction Journal (2017)
Bogenschutz, M. P., Forcehimes, A. A., Pommy, J. A. et al. · Journal of Psychopharmacology (2015)
Bornemann, J., Spriggs, M. J., Carhart-Harris, R. L. et al. · Frontiers in Psychiatry (2021)
Castellanos, J. P., Woolley, C., Bruno, K. A. et al. · Regional Anesthesia and Pain Medicine (2020)
Elman, I., Borsook, D., Pustilink, A. · Neuroscience and Biobehavioral Reviews (2022)
Glynos, N. G., Pierce, J., Davis, A. K. et al. · Journal of Psychoactive Drugs (2022)
Hutten, N. P. W., Mason, N. L., Dolder, P. C. et al. · Frontiers in Psychiatry (2019)
Johnson, M. W., Garcia-Romeu, A., Cosimano, M. P. et al. · Journal of Psychopharmacology (2014)
Johnson, M. W., Garcia-Romeu, A., Griffiths, R. R. · The American Journal of Drug and Alcohol Abuse (2016)
Mitchell, J., Bogenschutz, M. P., Lilienstein, A. et al. · Nature Medicine (2021)
Show all 16 referencesShow fewer
Polito, V., Stevenson, R. J. · PLOS ONE (2019)
Ramachandran, V., Chunharas, C., Marcus, Z. et al. · Neurocase (2018)
Ramaekers, J. G., Hutten, N. P. W., Mason, N. L. et al. · Journal of Psychopharmacology (2020)
Schindler, E. A. D., Gottschalk, C. H., Weil, M. J. et al. · Journal of Psychoactive Drugs (2015)
Schindler, E. A. D., Sewell, R. A., Gottschalk, C. H. et al. · Neurotherapeutics (2021)
Sewell, R. A. · Neurology (2006)
Cited By (4)
Papers in Blossom that reference this study
Aday, J. S., Mcafee, J., Conroy, D. A. et al. · Frontiers in Pain Research (2025)
Syed, O. A., Petranker, R., Fewster, E. C. et al. · Journal of Psychoactive Drugs (2024)
Polito, V., Liknaitzky, P. · Journal of Psychopharmacology (2024)
Schindler, E. A. D. · Current Pain and Headache Reports (2023)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.